Surgery – Diagnostic testing – Detecting nuclear – electromagnetic – or ultrasonic radiation
Reexamination Certificate
2000-03-03
2004-03-16
Shaw, Shawna J (Department: 3737)
Surgery
Diagnostic testing
Detecting nuclear, electromagnetic, or ultrasonic radiation
C436S173000
Reexamination Certificate
active
06708053
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to methods to MR Spectroscopy.
2. Description of the Prior Art
Problems with determining brain functioning in the past have included determining when someone has reduced brain functioning due to a disease such as: Alzheimer's disease, due to a traumatic injury such as: a gun shot wound, etc., exposure to radiation, exposure to a biochemical agent, etc.
Current ways of determining brain functioning include standard IQ tests, neuropsychological tests etc. However, many of the most popular types of methods of determining brain functioning are subjective in nature and may depend on the quality of the test being administered or the skills of the person administering a particular test to an individual.
SUMMARY OF THE INVENTION
One object of the present invention is to provide a more reliable method for determining the brain functioning of an individual.
Another object of the present invention is to provide an objective test for determining the brain functioning of an individual.
Yet another object of the present invention is to provide a method for determining a decrease or increase in brain functioning of an individual.
Yet another object of the present invention is to provide a method that is able to determine if an individual has suffered a traumatic injury that affects brain functioning.
Yet another object of the present invention is to provide a method that is able to determine if an individual is suffering from a disease that affects brain functioning.
Yet another object of the present invention is to provide a method that is able to determine if an individual has been exposed to a chemical or biochemical agent that affects brain functioning.
Yet another object of the present invention is to provide a method that is able to determine if an individual has been exposed to radiation that affects brain functioning.
According to a first aspect of the present invention, there is provided a method for determining brain functioning comprising: measuring the concentration of at least one MRS-visible brain chemical in a portion of an individual's brain; and determining brain functioning in the individual based on the concentration of at least one MRS-visible brain chemical measured.
According to a second aspect of the present invention, there is provided a method for determining a change in brain functioning comprising: measuring a first concentration of at least one MRS-visible brain chemical in a first portion of a brain of an individual at a first time; measuring a second concentration of at least one MRS-visible brain chemical in a second portion of said brain of the individual at a second time; and determining a change in the brain functioning, if any, of the individual based on the difference between said second concentration of at least one MRS-visible brain chemical measured and said first concentration of at least one MRS-visible brain chemical measured.
According to a third aspect of the present invention, there is provided a method for determining a change in brain functioning comprising: measuring a current concentration of at least one MRS-visible brain chemical in a portion of an individual's brain; and determining a current brain functioning in the individual based on the concentration of at least one MRS-visible brain chemical measured; determining a change in brain functioning, if any, for the individual based on comparing said current brain functioning to a previously determined brain functioning for the individual.
According to a fourth aspect of the present invention, there is provided a method for determining a change in brain functioning comprising: measuring a first concentration of at least one MRS-visible brain chemical in a first portion of a brain of an individual; measuring a second concentration of said at least one MRS-visible brain chemical in a second portion of said brain of the individual; and comparing said second concentration of at least one MRS-visible brain chemical measured to said first concentration of at least one MRS-visible brain chemical measured.
Other objects and features of the present invention will be apparent from the following detailed description of the preferred embodiment.
REFERENCES:
patent: 4332566 (1982-06-01), Mazeski et al.
patent: 5200345 (1993-04-01), Young
patent: 5357959 (1994-10-01), Fishman
patent: 5617861 (1997-04-01), Ross et al.
patent: 5887588 (1999-03-01), Usenius et al.
patent: 6347239 (2002-02-01), Arnold et al.
Cruz et al. “Proton MR Spectroscopic Imaging of the Striatum in Parkinson's Disease,” Dec. 1996, Magnetic Resonance Imaging, vol. 15, No. 6, pp. 619-624.*
Christiansen et al. “Reduced N-Acetylaspartate Content in the Frontal Part of the Brain in Patients with Probable Alzheimer's Disease,” Jan. 1994, Magnetic Resonance Imaging, vol. 13, No. 3, pp. 457-462.*
Ryou et al. “Dementia in Parkinson's diease—Examination according to Wechsler adult intelligence scale”, Sep. 1997, Journal of the Neurological Sciences, vol. 150, Issue 1001, p. S319.*
Lucivero et al. “Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders,” Journal of the Neurological Sciences, vol. 150, Issue 1001, p. S316.*
Anderson et al., “Temporal Lobe pHiand IQ: No Consistent Correlation.”Intellegence1998; 26(2): 75-79.
Andreasen et al., “Intelligence and Brain Structure in Normal Individuals.”Am. J. Psychiatry1993; 150:130-134.
Barker et al., “Quantitative Proton Spectroscopy of Canine Brain: in Vivo and in Vitro Correlations.” MRM 1994; 32: 157-163.
Bates et al., “Inhibition of N-acetylaspartate production: implications for1H MRS studies in vivo.”NeuroReport1996; 7:1397-1400.
Brooks et al., “Relationship Between Neurometabolite Derangement and Neurocognitive Dysfunction in Systematic Lupus Erythematosus.”The Journal of Rheumatology1999; 26:81-85.
Brooks et al., “Reproducibility of1H-MRS In Vivo.”Magnetic Resonance in Medicine1999; 41:193-197.
Ceci et al., “Schooling, Intelligence, and Income.”American Psychologist1997; 52(10): 1051-1058.
Davie et al., “Proton Magnetic Resonance Spectroscopy of Systemic Lupus Erythematosus Involving the Central Nervous System.”J. Neurol.1995; 242: 522-528.
Deary et al., “Neuroscience and Human Intelligence Differences.”TINS1997; 20(8): 365-370.
Friedman et al., “Proton MR Spectroscopic Findings Correspond ot Neuropsychological Function in Traumatic Brain Injury.”AJNR Am. J. Neuroradiol1998; 19:1879-1885.
Freidman et al., “Quantitative proton MRS predicts outcome after traumatic brain injury.”Neurology1999; 52: 1384-1391.
Gadian et al., “Lateralization of brain function in childhood revealed by magnetic resonance spectroscopy.”Neurology1996; 46:974-977.
Haseler et al., “Proton MR Spectroscopic Meaurement of Neurometabolites in Hepatic Encephalopathy during Oral Lactulose Therapy.”AJNR Am. J. Neuroradiol1998; 19: 1681-1686.
Huda et al., “Clinical Correlation of Neuropsychological Tests With1H Magnetic Resonance Spectroscopy in Hepatic Encephalopathy.” Psychosomatic Medicine 1998; 60: 550-556.
Lopez-Villegas et al., “Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy.”Proc. Natl. Acad. Sci. USA1997; 94, 9854-9859.
Martin et al., “Brain Proton Magnetic Resonance Spectroscopy Studies in Recently Abstinent Alcoholics.”Alcohol Clin. Exp. Res.1995; 19(4): 1078-1082.
Matarazzo, “Psychological Testing and Assessment in the 21stCentury.”American Psychologist1992; 47(8): 1007-1018.
Mesulam, “Large Scale Neurocognitive Networks and Distributed Processing for Attention, Language, and Memory.”Ann. Neurol.1990; 28: 597-613.
Rae et al., “Brain biochemistry in Duchenne muscular dystrophy: A1H magnetic resonance and neuropsychological study.”Journal of Neurological Science1998; 160: 148-157.
Rae et al., “Brain biochemistry in Williams syndrome: Evidence for a role of the cerebellum in cognition?”Neurology1998; 51:33-40.
Rae et al., “Is pH a Biochemical Marker of IQ?”Proc. R. Soc. Lond.
Brooks William M.
Friedman Seth David
Jung Rex
Petropoulos Helen
Sibbitt Wilmer L.
Roberts Abokhair & Mardula LLC
Science and Technology Corp. @ UNM
Shaw Shawna J
LandOfFree
Biochemical markers of brain function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biochemical markers of brain function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biochemical markers of brain function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3251008